Lattuca-Truc M, et al. - Researchers examined 529 consecutive small-cell lung cancer (SCLC) patients, to compare the response to chemotherapy and survival between 1997-2009 (period 1) and 2010-2017 (period 2). A first line of chemotherapy and a second line of chemotherapy was received by 498 and 279 patients, respectively. Extensive disease was detected in most of the cases (n = 290, 58%). In metastatic patients, 63% and 62% were the objective response rate (ORR) to first-line chemotherapy in period 1 and in period 2, respectively; for second-line chemotherapy, the respective ORRs were 39% and 29%. In period 1 and in period 2, the observed median overall survival from first-line chemotherapy was 13.2 months and 11.2 months, respectively. Cardiovascular comorbidities, liver comorbidities, poor ECOG performance status and extensive disease were all independently related to mortality. Survival or response rate to chemotherapy of SCLC patients did not improve since 1997. Findings call for new approaches in this setting.